17.07.2014 • NewsDede WillamsLuciano RossettiMerck

Luciano Rossetti Moves from Merck to Merck

Merck Serono, the biopharmaceutical division of Germany's Merck KGaA has appointed Luciano Rossetti as executive vice president and global head of research & development with effect from July 2.

Rossetti most recently was Senior Vice President Late Stage Development at US pharmaceutical producer Merck Sharp & Dohme, where he was responsible for the entire clinical development from Phase II to Phase V across all therapeutic areas.

The new R&D chief will be based in Billerica, outside Boston, Massachusetts, in the US, one of Merck Serono's four global R&D hubs, and will share his time between Merck's headquarters in Darmstadt, Germany, and Billerica.

Interview

Stability in Motion
Strategic Response to a Shifting Pharma Landscape

Stability in Motion

Stefan Oelrich, Member of the Board of Management and President Pharmaceuticals, Bayer, discusses navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.

Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

most read

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.